Navigation Links
Anesiva and Transcription Factor Therapeutics, Inc. Announce Licensing Agreement for Development and Commercialization of NF-kappa B Clinical Program
Date:6/5/2008

ientific meetings and are published in DeVry et al., (2007) Gut 56(4):524-33 "Non-viral delivery of nuclear factor-kappaB decoy ameliorates murine inflammatory bowel disease and restores tissue homeostasis." Avrina has been evaluated for safety, tolerability and anti- inflammatory drug effect in an exploratory, dose-ranging US Phase I clinical study for treatment of atopic dermatitis.

"TFT is extremely pleased to expand its development program to include the Avrina(TM) assets," said Ryan Rauch, President and COO of TFT. "Avrina(TM) may have the potential to provide durable, long-lasting inflammation reduction while providing patients with more convenient dosing regimens and fewer side effects. The extremely positive pre-clinical IBD data, together with the demonstrated safety and biological activity demonstrated in Anesiva's first- in-man studies with Avrina(TM), will help push our IBD program into the clinic in 2009. This will also help leverage our existing Atopic Dermatitis program that is scheduled to begin Phase II clinical testing in the U.S. in the second half of 2009."

About Anesiva and its Pipeline of Pain Products

Anesiva, Inc. is a late-stage biopharmaceutical company that seeks to be the leader in the development and commercialization of novel pharmaceutical products for pain management. The company has one FDA-approved product, Zingo, for the reduction of pain associated with peripheral venous access procedures in children ages 3 to 18. The second product in Anesiva's pipeline, Adlea(TM), has been shown to reduce pain after only a single administration for weeks to months in multiple settings in numerous mid-stage clinical trials for site- specific, acute and chronic, moderate-to-severe pain. Anesiva is based in South San Francisco, CA. For more information about Anesiva's leadership in the development of products for pain management, and an overview of the clinical challenges being addressed by its product candidates, go to '/>"/>

SOURCE Anesiva, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related biology technology :

1. Anesiva Announces First Quarter 2008 Financial Results
2. Anesiva Announces First Quarter 2008 Financial Results Conference Call and Webcast
3. Anesiva Announces Expansion of Zingo Agreement in Europe
4. Anesiva Announces New Zingo Marketing and Distribution Agreement
5. Anesiva Announces Submission of Supplemental New Drug Application for Zingo(TM) to Reduce Pain Associated With Needle Insertion Procedures in Adults
6. Anesiva Announces March 5, 2008 Presentation at Susquehanna Financial Group Healthcare Conference
7. Anesiva Announces Fourth Quarter and Year-End 2007 Financial Results and Provides 2008 Outlook
8. Anesiva Appoints Daniel Janney to Board of Directors
9. Anesiva Announces Fourth Quarter and Year End 2007 Financial Results Conference Call and February 2008 Conference Participation
10. Anesiva Announces Completion of Common Stock Offering
11. Anesiva Raises $45 Million in Common Stock Offering

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/30/2009)...MSTERDAM, November 30 El...c, medical and technical products and services,to...prehensive biomedical,database which holds over 20...ve, peer reviewed journals. , Embase has ...iomedical,and pharmaceutical insights. Now, new de...
(Date:11/28/2009)...onal Advisory Committee on Climate Change (NACCC) ...oject in collaboration with the Vanuatu Meteorolog...have generated preliminary climate change and sea ...or the country’s SNC reporting to the United...NFCCC). , Port Vila, Van...
(Date:11/27/2009)...wire-FirstCall/ -- Stallergenes has been,granted E...ts and children,through a Mutual Recognition Proce...has been marketed, was the reference Member state....a, Belgium, Bulgaria, Cyprus, the,Czech Republic, ..., Italy,Latvia, Lithuania, Luxembourg, Malta, the...
(Date:11/26/2009)...ion of ultrasmall transistors and more powerful co...ucting nanowires are closer to reality after a key...y and the University of California at Los Angeles....nowires with layers of different materials that ar...critical requirement for making efficient transist...
Breaking Biology Technology:Elsevier is Re-Launching "Embase" to be a Powerful Resource Providing Deep Insights and Answers to Biomedical Researchers 2Elsevier is Re-Launching "Embase" to be a Powerful Resource Providing Deep Insights and Answers to Biomedical Researchers 3Preliminary Climate and Sea Level Changes for Vanuatu Through the Application of SimCLIM 2Preliminary Climate and Sea Level Changes for Vanuatu Through the Application of SimCLIM 3Preliminary Climate and Sea Level Changes for Vanuatu Through the Application of SimCLIM 4STALLERGENES is Granted a Marketing Authorization for Oralair(R) in Europe 2STALLERGENES is Granted a Marketing Authorization for Oralair(R) in Europe 3Nanowires key to future transistors, electronics 2Nanowires key to future transistors, electronics 3
...aGen to receive approximately $45 million in cash,...ne payments - - Provides updated financ...o be hosted today at 9:00 a.m. EDT -, BRANFORD, C... ), a clinical-stage biopharmaceutical company, an...linostat, a Phase I/II histone,deacetylase inhibit...
...LLE, Calif., April 21 Ortho Evra is an adhesive,t...release 150 mcg of,norelgestromin and 20 mcg of et... It is replaced once a week for three weeks, and n... was approved by the FDA in November,2001, and ove...pproval.,Ortho Evra continues to be marketed aggre...
... Million Net Revenues, $0.03 Net Loss Per Share, ...logies, Inc. (Nasdaq: VNUS ), a leading provider ...tment of venous disease, today announced its,finan... 2008., Net revenues for the first quarter of 200....6 million for the first quarter of 2007. As,expec...
Other Biology Technology:CuraGen Sells Ownership of Belinostat to TopoTarget A/S 2CuraGen Sells Ownership of Belinostat to TopoTarget A/S 3CuraGen Sells Ownership of Belinostat to TopoTarget A/S 4CuraGen Sells Ownership of Belinostat to TopoTarget A/S 5Ortho Evra Patch Makers Settling Cases 2VNUS Medical Technologies Reports First-Quarter 2008 Results: 21% growth in Net Revenues and 51% Growth in Unit Sales 2VNUS Medical Technologies Reports First-Quarter 2008 Results: 21% growth in Net Revenues and 51% Growth in Unit Sales 3VNUS Medical Technologies Reports First-Quarter 2008 Results: 21% growth in Net Revenues and 51% Growth in Unit Sales 4VNUS Medical Technologies Reports First-Quarter 2008 Results: 21% growth in Net Revenues and 51% Growth in Unit Sales 5VNUS Medical Technologies Reports First-Quarter 2008 Results: 21% growth in Net Revenues and 51% Growth in Unit Sales 6VNUS Medical Technologies Reports First-Quarter 2008 Results: 21% growth in Net Revenues and 51% Growth in Unit Sales 7
(Date:11/30/2009)..., New Orleans, LA Researchers from LSU Health Sc... Eunice Kennedy Shriver National Institute of Chil...hool of Public Health, Brigham and Women,s Hospita...first time that drinking more than 5 servings of s...ears to significantly elevate the risk of developi...
(Date:11/30/2009)..., Two so-called invasion proteins are crucial for...surface of human cells, which stimulates the host ...ptor molecules exert a different function, for exa...ng. The group,s results have now been published in...iology ". , Spoiled meat is one of the sources f...
(Date:11/30/2009)..., If you ever thought the stress of seeing your e...g youbad news: a new research report in the Decemb...iology ( http://www.jleukbio.org ) shows that you...m the same study might lead to entirely new treatm..., arthritis, and eczema under control. That,s beca...
Breaking Biology News(10 mins):Sugary cola drinks linked for first time to higher risk of gestational diabetes 2Sugary cola drinks linked for first time to higher risk of gestational diabetes 3It takes 2 to infect 2Seeing family for the holidays? Scientists discover how the stress might kill you 2UCR scientists manipulate ripples in graphene enabling strain based graphene electronics 13195 1UCR scientists manipulate ripples in graphene enabling strain based graphene electronics 13195 2UCR scientists manipulate ripples in graphene enabling strain based graphene electronics 13195 3Surgery remans an option for advanced lung cancer 52719 1Surgery remans an option for advanced lung cancer 52719 2Common allergy drug reduces obesity and diabetes in mice 9359 1Common allergy drug reduces obesity and diabetes in mice 9359 2Common allergy drug reduces obesity and diabetes in mice 9359 3Common allergy drug reduces obesity and diabetes in mice 9359 4
...rcent of women rely on their healthcare providers ...ercent said their doctor has talked to them about ...avirus (HPV) - according to a new survey released ...onals (ARHP). HPV is extremely common, affecting a...n their lifetime, in some cases staying dormant un...
...r manipulating macromolecules has been developed b...ana-Champaign. The technique uses double-stranded ...In previous DNA nanotechnology efforts, duplex DNA...ometrical objects in three dimensions. Instead of ...rchers are using DNA to control the folding and re...
...r manipulating macromolecules has been developed b...ana-Champaign. The technique uses double-stranded ...In previous DNA nanotechnology efforts, duplex DNA...ometrical objects in three dimensions. Instead of ...rchers are using DNA to control the folding and re...
Other Biology News:Survey reveals women and doctors aren't talking about HPV 2Survey reveals women and doctors aren't talking about HPV 3Health costs soar as 60 million Americans classed as obese 2UN successfully tests 'green' pesticide against locusts 2
Human Mesenchymal Stem Cell Functional Identification Kit from R&D Systems
Goat Anti-Human Carnosine Dipeptidase 1 Polyclonal Antibody, Unconjugated from R&D Systems
Rabbit Anti-Syntrophin alpha 1 Polyclonal Antibody, Unconjugated from Abcam
Mouse Anti-VEGF Receptor 1 Monoclonal Antibody, Unconjugated, Clone Flt-1 / EWC from Abcam
Biology Products: